Pemigatinib dosage

Pemigatinib (Pemigatinib) is used to treat adult cholangiocarcinoma with FGFR2 rearrangement and myeloid/lymphoid tumors with FGFR1 rearrangement. Pemigatinib tablets are uncoated and are intended for oral administration. Tablets contain4.5mg, 9mg or 13.5mg of the active ingredient , the recommended dose for cholangiocarcinoma is 13.5mg once daily for the first 14 days of a 21-day cycle. For other tumors, the recommended dose is 13.5 mg daily until disease progression or unacceptable toxicity.

Adverse events with pemetinib are common and often include hyperphosphatemia (an effect of inhibiting FGF signaling), as well as fatigue, nausea, diarrhea, constipation, dysgeusia, anorexia, abdominal pain, musculoskeletal pain, dizziness, alopecia, dryness of the eyes, mouth, and skin, blurred vision, nail poisoning, and symptoms of hand-foot syndrome. Serious adverse events included ocular toxicity, severe hyperphosphatemia, and embryo-fetal toxicity.

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).